Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Fox

Showing results (71-80 of 141) with videos related to

Pageof 15
Sort By:
Vaccine|March 20, 2016
Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigenSusan L Baldwin, Will Roeffen, Susheel K Singh, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 13, 2013
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosisMark T Orr, Christopher B Fox, Susan L Baldwin, et al.
Vaccine|August 10, 2017
Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccinesJames D Allen, Simon O Owino, Donald M Carter, et al.
Vaccine|March 24, 2023
Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvantWaranyoo Phoolcharoen, Balamurugan Shanmugaraj, Narach Khorattanakulchai, et al.
International Journal of Pharmaceutics|December 5, 2020
Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidateMellissa Gomez, Joseph McCollum, Hui Wang, et al.
Frontiers in Immunology|May 18, 2026
ID93 + GLA-3M-052-LS vaccine candidate administered by heterologous routes improves BCG efficacy against TBEmily Voigt, Anas Alsharaydeh, Darshan N Kasal, et al.
Vaccine|March 20, 2012
Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in miceJoanne M Lumsden, Saule Nurmukhambetova, Jennifer H Klein, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|March 23, 2021
Microparticle encapsulation of a tuberculosis subunit vaccine candidate containing a nanoemulsion adjuvant via spray dryingMellissa Gomez, Michelle Archer, David Barona, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 3, 2014
Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilizationMark T Orr, Ryan M Kramer, Lucien Barnes, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
The ID93 + GLA-3M-052-LS vaccine candidate elicits mucosal and systemic immunogenicity and protective efficacy against <i>Mycobacterium tuberculosis</i> challenge in BCG-primed Collaborative Cross inbred miceEmily A Voigt, Anas Alsharaydeh, Darshan N Kasal, et al.
Pageof 15

Showing results (71-80 of 141) with videos related to

Sort By:
Pageof 15
Vaccine|March 20, 2016
Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigenSusan L Baldwin, Will Roeffen, Susheel K Singh, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 13, 2013
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosisMark T Orr, Christopher B Fox, Susan L Baldwin, et al.
Vaccine|August 10, 2017
Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccinesJames D Allen, Simon O Owino, Donald M Carter, et al.
Vaccine|March 24, 2023
Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvantWaranyoo Phoolcharoen, Balamurugan Shanmugaraj, Narach Khorattanakulchai, et al.
International Journal of Pharmaceutics|December 5, 2020
Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidateMellissa Gomez, Joseph McCollum, Hui Wang, et al.
Frontiers in Immunology|May 18, 2026
ID93 + GLA-3M-052-LS vaccine candidate administered by heterologous routes improves BCG efficacy against TBEmily Voigt, Anas Alsharaydeh, Darshan N Kasal, et al.
Vaccine|March 20, 2012
Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in miceJoanne M Lumsden, Saule Nurmukhambetova, Jennifer H Klein, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|March 23, 2021
Microparticle encapsulation of a tuberculosis subunit vaccine candidate containing a nanoemulsion adjuvant via spray dryingMellissa Gomez, Michelle Archer, David Barona, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 3, 2014
Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilizationMark T Orr, Ryan M Kramer, Lucien Barnes, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
The ID93 + GLA-3M-052-LS vaccine candidate elicits mucosal and systemic immunogenicity and protective efficacy against <i>Mycobacterium tuberculosis</i> challenge in BCG-primed Collaborative Cross inbred miceEmily A Voigt, Anas Alsharaydeh, Darshan N Kasal, et al.
Pageof 15